Travere Therapeutics, Inc. Common Stock (TVTX) is a publicly traded Healthcare sector company. As of May 21, 2026, TVTX trades at $42.86 with a market cap of $3.99B and a P/E ratio of -148.83. TVTX moved +2.91% today. Year to date, TVTX is +14.12%; over the trailing twelve months it is +147.66%. Its 52-week range spans $12.91 to $48.61. Analyst consensus is strong buy with an average price target of $53.42. Rallies surfaces TVTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
TVTX financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. TVTX recently traded at $42.86. Market cap is $3.99B. P/E ratio is -148.83. Revenue is $490.73M.
| Metric | Value |
|---|---|
| Price | $42.86 |
| Market Cap | $3.99B |
| P/E Ratio | -148.83 |
| EPS | $-0.29 |
| Dividend Yield | 0.00% |
| 52-Week High | $48.61 |
| 52-Week Low | $12.91 |
| Volume | 22 |
| Avg Volume | 0 |
| Revenue (TTM) | $490.73M |
| Net Income | $-25.55M |
| Gross Margin | 97.89% |
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $490.73M | $-25.55M | $-0.29 |
| 2023 | $145.24M | $-111.40M | $-1.50 |
| 2022 | $212.02M | $-278.48M | $-4.37 |
| 2021 | $227.49M | $-180.09M | $-3.01 |
13 analysts cover TVTX: 0 strong buy, 12 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $53.42.